Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Lung cancer biomarker testing : perspective from Europe
Authors:ID Thunnissen, Erik (Author)
ID Weynand, Birgit (Author)
ID Udovicic-Gagula, Dalma (Author)
ID Brčić, Luka (Author)
ID Szolkowska, Malgorzata (Author)
ID Hofman, Paul (Author)
ID Smojver-Ježek, Silvana (Author)
ID Anttila, Sisko (Author)
ID Calabrese, Fiorella (Author)
ID Kern, Izidor, Klinika Golnik (Author)
Files:.pdf PDF - Presentation file, download (1,80 MB)
MD5: 08500071FD4E2273A0DACAEECA7E7FDB
 
URL URL - Source URL, visit http://tlcr.amegroups.com/article/view/40413/pdf
 
Language:English
Typology:1.02 - Review Article
Organization:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:A questionnaire on biomarker testing previously used in central European countries was extended and distributed in Western and Central European countries to the pathologists participating at the Pulmonary Pathology Society meeting 26-28 June 2019 in Dubrovnik, Croatia. Each country was represented by one responder. For recent biomarkers the availability and reimbursement of diagnoses of molecular alterations in non-small cell lung carcinoma varies widely between different, also western European, countries. Reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. The support for testing from alternative sources, such as the pharmaceutical industry, is no doubt partly compensating for the lack of public health system support, but it is not a viable or long-term solution. Ideally, a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. As biomarker enabled therapies deliver a 50% better probability of outcome success, improved and unbiased reimbursement remains a major challenge for the future.
Keywords:lung neoplasms -- diagnosis -- therapy -- Europe, lung cancer, predictive testing
Publication status:Published
Publication version:Version of Record
Place of publishing:Kitajska
Publisher:AME Publishing
Year of publishing:2020
Number of pages:str. 887-897
Numbering:Vol. 9, iss. 3
PID:20.500.12556/DiRROS-12421 New window
UDC:616-006
ISSN on article:2226-4477
COBISS.SI-ID:28071683 New window
Copyright:© Translational Lung Cancer Research
Note:Nasl. z nasl. zaslona; Soavtor iz Slovenije: Izidor Kern; Opis vira z dne 11. 9. 2020;
Publication date in DiRROS:21.09.2020
Views:2479
Downloads:1351
Metadata:XML DC-XML DC-RDF
:
THUNNISSEN, Erik, WEYNAND, Birgit, UDOVICIC-GAGULA, Dalma, BRČIĆ, Luka, SZOLKOWSKA, Malgorzata, HOFMAN, Paul, SMOJVER-JEŽEK, Silvana, ANTTILA, Sisko, CALABRESE, Fiorella and KERN, Izidor, 2020, Lung cancer biomarker testing : perspective from Europe. Translational lung cancer research [online]. 2020. Vol. 9, no. 3, p. 887–897. [Accessed 8 April 2025]. Retrieved from: https://dirros.openscience.si/IzpisGradiva.php?lang=eng&id=12421
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Translational lung cancer research
Shortened title:Transl. lung cancer res.
Publisher:Pioneer Bioscience
ISSN:2226-4477
COBISS.SI-ID:17120003 New window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Licensing start date:27.05.2020

Secondary language

Language:Undetermined
Keywords:pljučne novotvorbe -- diagnostika -- terapija -- Evropa, pljučni rak, napovedno testiranje


Back